TargetMol

Naproxcinod

Product Code:
 
TAR-T33595
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T33595-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33595-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T33595-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Naproxcinod, a nitric oxide-releasing NSAID derivative, significantly improved skeletal muscle strength and fatigue resistance in sedentary and exercise mice, reducing inflammatory infiltration and fibrotic deposition in the myocardium and diaphragm. In addition to its anti-inflammatory activity, Naproxcinod is a promising candidate for the treatment of Duchenne muscular dystrophy.
CAS:
163133-43-5
Formula:
C18H21NO6
Molecular Weight:
347.37
Purity:
0.98
SMILES:
C[C@@H](C1=CC=C2C=C(OC)C=CC2=C1)C(OCCCCO[N+]([O-])=O)=O

References

Li X, Zhang J, Bao Y, Ye Y, Li W, Yin W, Guo F, Chen A. WITHDRAWN: Efficacy and safety of short-term treatment of naproxcinod in patients with osteoarthritis (OA) of the hip: A prospective, randomized study. Arch Gerontol Geriatr. 2015 Jan 31. pii: S0167-4943(15)00013-8. doi: 10.1016/j.archger.2015.01.012. [Epub ahead of print] PubMed PMID: 25912890. Uaesoontrachoon K, Quinn JL, Tatem KS, Van Der Meulen JH, Yu Q, Phadke A, Miller BK, Gordish-Dressman H, Ongini E, Miglietta D, Nagaraju K. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49. doi: 10.1093/hmg/ddu033. Epub 2014 Jan 23. PubMed PMID: 24463621; PubMed Central PMCID: PMC4030778. Shi X, Shang W, Wang S, Xue N, Hao Y, Wang Y, Sun M, Du Y, Cao D, Zhang K, Shi Q. Simultaneous quantification of naproxcinod and its active metabolite naproxen in rat plasma using LC-MS/MS: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:157-62. doi: 10.1016/j.jchromb.2014.12.001. Epub 2014 Dec 11. PubMed PMID: 25550191. Miglietta D, De Palma C, Sciorati C, Vergani B, Pisa V, Villa A, Ongini E, Clementi E. Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy. Orphanet J Rare Dis. 2015 Aug 22;10:101. doi: 10.1186/s13023-015-0311-0. PubMed PMID: 26296873; PubMed Central PMCID: PMC4546261.